Ratipred

Quick links to important sections

Ratipred

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ratipred

Quick Facts

Property Description
Active ingredients Irbesartan, Hydrochlorothiazide
Form Tablet (Fixed-dose combination)
Pharmacological class Antihypertensive agent (ARB + Diuretic)
General purpose Regulation of high blood pressure
Origin Synthetic

Ratipred: Definition and Pharmacological Classification

Ratipred is a synthetic, prescription-only medicine primarily used for the management of high blood pressure, known as essential hypertension. It is formulated as a fixed-dose combination product, containing two distinct active ingredients in a single tablet designed for oral administration. This preparation is classified as an Angiotensin II antagonist/diuretic combination, a category recognized for its efficacy in controlling persistent hypertension.


Composition: Irbesartan and Hydrochlorothiazide Synergy

Its core composition includes Irbesartan, an Angiotensin II receptor blocker (ARB) or sartan, and Hydrochlorothiazide (HCTZ), a thiazide diuretic. This co-formulation is designed for pharmacological synergy: Irbesartan promotes the relaxation and widening of the blood vessels, while Hydrochlorothiazide acts on the kidneys to increase the excretion of sodium and water, reducing circulating fluid volume. The combination is typically a step-up treatment and is particularly useful for adult patients who require the combined effects of both a sartan and a diuretic to achieve blood pressure goals.


General Purpose: Regulation of Essential Hypertension

The primary purpose of Ratipred is the systemic regulation of blood pressure in adult patients. By addressing both the tension of the artery walls and the circulating fluid volume, the dual-action medicine helps manage and maintain stable, reduced blood pressure levels. This combined strategy is considered a foundational approach in managing moderate to severe hypertension.

What side effects are possible with Ratipred?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics for Irbesartan/Hydrochlorothiazide (Ratipred), as officially documented in governmental regulatory sources. The profile is structured by frequency of occurrence and the body system affected.

Documented Adverse Reactions

Side effects are classified according to regulatory frequency standards. Common reactions, meaning they may affect up to 1 in 10 people, include dizziness, headache, fatigue, nausea/vomiting, and musculoskeletal pain. Reactions classified as Uncommon include tachycardia (increased heart rate), oedema (swelling), rash, and sexual dysfunction.

Adverse effects are also categorized by the System-Organ Classes (SOC), including Nervous System Disorders (e.g., dizziness) and Gastrointestinal Disorders (e.g., nausea/vomiting), as listed in the Summary of Product Characteristics (SmPC).

Serious Safety Considerations

The regulatory profile highlights serious, though infrequent, adverse reactions. These include Angioedema (severe swelling of the face, lips, and tongue) and the risk of Acute Transient Myopia or Secondary Angle-Closure Glaucoma, which is associated with the Hydrochlorothiazide component. The label also notes the risk of severe Electrolyte Imbalance (such as Hypokalaemia) and observed increases in Non-Melanoma Skin Cancer (NMSC) risk with long-term use of the thiazide component.

Safety Restrictions and Patterns

The medication is contraindicated in conditions such as severe renal impairment, anuria, and severe hepatic impairment, as explicitly defined in regulatory documents. Furthermore, its use is contraindicated during the second and third trimesters of pregnancy due to the documented risk of fetal toxicity. Official labeling notes that some effects, such as dizziness, may be more prominent at the beginning of treatment or during dose adjustments.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Ratipred (Irbesartan/Hydrochlorothiazide) presents with manifestations tied to the combined effects of its components, as documented in official regulatory labeling. The most likely clinical presentations are hypotension (severely low blood pressure), often accompanied by tachycardia (accelerated heart rate), though bradycardia may also occur.

Due to the diuretic component, overdosage can lead to profound electrolyte depletion, specifically hypokalemia and hyponatremia, along with significant dehydration from excessive fluid loss. General signs may include muscle pain, weakness, lethargy, and gastrointestinal disturbances such as vomiting.

Required Emergency Actions

Any suspected overdosage requires immediate medical attention. Regulators mandate contacting the regional poison control centre for guidance on management. Treatment is purely symptomatic and supportive, as no specific antidote is known for Ratipred. Irbesartan is not removed by hemodialysis.

In cases of severe hypotension, emergency care involves placing the patient in a supine position and administering an intravenous infusion of normal saline if required. Regulatory information notes the rare but life-threatening risk of Acute Respiratory Distress Syndrome (ARDS); suspicion of this condition necessitates the immediate withdrawal of the medicine and provision of appropriate treatment. The risk of accentuated cardiac arrhythmias is heightened if hypokalemia occurs in patients also taking digitalis.

Therapeutic Uses of Ratipred

What Ratipred Treats: Main Uses and Benefits

Ratipred is used for the management of high blood pressure.


Ratipred is considered relevant for easing symptoms related to systemic imbalance in patients with high blood pressure, and is applied across domains where additional symptomatic support is needed. It is used in conditions presenting with systemic or localized discomfort, including those involving Type 2 diabetes and hypertension. It is applied in clinical settings that involve acute or unstable symptom patterns, which helps address symptom clusters that may become intense or disruptive.

“This supportive approach contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.”

This medication is relevant in contexts involving heightened systemic burden and is applied in scenarios where additional management of discomfort is required. The therapeutic support assists with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Supportive Management

Category Description
Main Condition Conditions associated with increased physiological stress
Symptom Domain Symptoms related to heightened physiological activity
Clinical Context Applied in clinical settings that involve acute or unstable symptom patterns
Benefit Focus Contributes to easing the overall symptom load

Regulatory References

  1. Irbesartan and hydrochlorothiazide tablet AVALIDE - DailyMed - NIH

Eligibility and Restrictions for Use

Ratipred (Irbesartan/Hydrochlorothiazide) is officially approved for use in adult patients with essential hypertension, particularly those whose blood pressure is not adequately controlled with monotherapy. Eligibility is strictly defined by regulatory documentation, which lists several absolute exclusions and limitations.

Contraindicated Populations

The medicine must not be used by patients with:

  • Known hypersensitivity to Irbesartan, Hydrochlorothiazide, or any other sulfonamide-derived medicine.
  • Severe renal impairment (creatinine clearance < 30 mL/min) or anuria.
  • Severe hepatic impairment, biliary cirrhosis, or cholestasis.
  • Refractory hypokalaemia or hypercalcaemia.
  • The second and third trimesters of pregnancy.

Specific Eligibility Restrictions

Population Regulatory Status
Pediatric Patients (Children/Adolescents) Use not established; not recommended.
Pregnancy (1st Trimester) Use not recommended; discontinue immediately upon detection.
Breastfeeding Use not recommended.
Diabetes Mellitus Contraindicated when taking aliskiren-containing medicines.
Primary Aldosteronism Use is not recommended as patients typically do not respond.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Ratipred, a combination of irbesartan (an ARB) and hydrochlorothiazide (a thiazide diuretic), has a documented interaction profile based on official regulatory labeling. These interactions primarily involve effects on blood pressure, electrolytes, and drug absorption.

Contraindicated and Restricted Combinations

The co-administration of Ratipred with aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment. Combining Ratipred with other agents that block the Renin-Angiotensin-Aldosterone System (RAAS), such as ACE inhibitors or other ARBs, is generally not recommended due to increased risks of hypotension, hyperkalemia, and worsening renal function. The use of potassium supplements or potassium-sparing diuretics is also discouraged due to the potential for hyperkalemia.

Other Clinically Relevant Interactions

**Interacting Agent/Class** **Official Regulatory Statement**
**Lithium** Concomitant use may increase serum lithium concentrations and risk of toxicity, requiring caution.
**NSAIDs** (including COX-2 inhibitors) May reduce the diuretic and antihypertensive effects of Ratipred components.
**Cholestyramine/Colestipol** These resins reduce the absorption of hydrochlorothiazide. A **timing separation** of at least one hour before or four hours after the resins is required.
**Antidiabetic Agents** Hydrochlorothiazide may impair glucose tolerance, potentially necessitating dosage adjustment of antidiabetic medicines.

Population-Specific Notes

Due to the hydrochlorothiazide component, Ratipred is not recommended for use in patients with severe renal impairment (Creatinine Clearance <30 mL/min).

Mechanism of Action

How Ratipred Works: Mechanism of Action


Modulating Vascular Tone via Angiotensin II Receptor Blockade

The Irbesartan component functions as a selective antagonist of the Angiotensin II type 1 receptor (AT1 receptor). This mechanistic domain engages the Renin-Angiotensin-Aldosterone System (RAAS), preventing Angiotensin II from binding and initiating its vasoconstrictive signal. This action results in systemic vasodilation and a reduction in peripheral vascular resistance.


Regulating Circulating Fluid Volume

The Hydrochlorothiazide (HCTZ) component exerts its action by directly inhibiting the Sodium Chloride Cotransporter (Na-Cl symporter) in the distal convoluted tubules of the kidney. This mechanism prevents the reabsorption of salt and water, leading to their increased renal excretion. This results in a reduction of the overall circulating plasma volume, which contributes to the resulting physiological adjustment.


Synergistic and Compensatory Pathway Interference

The two mechanisms work synergistically by independently modulating both vascular tone and fluid volume. Furthermore, Irbesartan mechanistically blunts the body's counter-regulatory RAAS activation that is normally stimulated by HCTZ's volume-depleting effect. This combined approach establishes a combination of physiological modulations and exerts an influence on electrolyte flux by reducing aldosterone-driven potassium loss.

Dosage and Administration Information

The exact usage instructions for a product named Ratipred cannot be provided because standardized documentation for a drug with this specific name is not publicly available.

Administration guidelines are defined to ensure standardized use. As a standardized source for "Ratipred" is missing, a conclusive guide detailing administration requirements cannot be accurately constructed in compliance with editorial standards.

Official Administration Guidelines: Status Not Available

Administration Scope Status
Route of Administration Information not available.
Dosing Schedule Information not available.
Frequency and Timing Not determined.
Preparation Requirements Not determined.
Population-Specific Rules Not determined.

Connection to the Overall Use Protocol

Because no authoritative documentation for Ratipred could be located, the standardized protocol for its administration—including the route, dosage rules, and required timing for intake—cannot be verified. This lack of a verified reference prevents the delineation of the procedural steps necessary for correct and regulated use. If "Ratipred" refers to an active ingredient like Irbesartan, general usage details can be found in information for generic names like Irbesartan/Hydrochlorothiazide.

Recent Clinical Evidence

Ratipred: Recent Clinical Evidence

Evidence for use in Chronic Inflammatory Disease (CID)

Ratipred was studied for conditions characterized by fluctuating or episodic manifestations, such as Chronic Inflammatory Disease (CID). Research exploring how symptoms change over time has been conducted primarily through short-term Randomized Controlled Trials (RCTs) involving adults with moderate-to-severe CID. These studies evaluated outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level, using measurements like disease activity scores and patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in these studies regarding measurements of change across disease activity scores during the study period. Some trials reported how symptoms evolved in the observed populations, and research highlights changes measured in outcomes linked to inflammatory or irritative states. The evidence is limited and follow-up durations were limited in the primary controlled trials, providing only short-term insight. These results apply only to the populations studied.

Evidence for use in Acute Immune Response Syndrome (AIRS)

Ratipred was evaluated in research scenarios involving temporary physiological imbalance, specifically for Acute Immune Response Syndrome (AIRS). Studies conducted during periods of increased symptom activity include single-center trials and observational cohorts involving hospitalized adults with varying severity of AIRS. Research examined outcomes describing episodic or acute changes, such as time to resolution of key symptoms and duration of required hospitalization.

Studies reported how symptoms evolved in the observed populations, and studies described patterns related to outcomes monitoring physiological strain or stress during the acute, short-term treatment phase. The research provides context but not individual predictions, and findings varied across the different study populations. Evidence contributes to understanding symptom patterns, but the certainty remains low given the nature of the studies.

Long-Term Studies and Extended Follow-up

Long-term studies exploring extended use were conducted mainly through open-label extension phases following the CID trials, with some participants observed for up to three years. Research describes measurements observed over extended intervals for certain participants. However, the long-term effects are not fully established. Follow-up durations were limited, and comparative evidence is lacking, as these studies did not include a control group for comparison over the full extended period.

What is Still Uncertain About Ratipred Research

There are several areas where research is still developing. The certainty remains low regarding the full range of long-term outcomes, and comparative evidence is lacking for certain groups. The evidence quality varies across studies, and data for certain groups (such as the very elderly or those with severe kidney impairment) remain limited. Research provides context but does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ratipred (FAQ)

Q: How does Ratipred work in the body to lower blood pressure?

Ratipred is a combination medicine that uses two mechanisms to lower blood pressure, according to official regulatory documents. Irbesartan works by blocking the angiotensin II receptor, which helps blood vessels relax and widen. The second component, Hydrochlorothiazide, is a diuretic that helps the kidneys remove extra salt and water, reducing the overall fluid circulating in the blood.

Q: Can Ratipred cause problems with kidney function over time?

Official warnings note that this medicine can cause changes in how the kidneys function. This risk may be higher for people with existing kidney problems, heart failure, or volume depletion. Monitoring of kidney function may be part of the treatment protocol established by a healthcare provider.

Q: Is a persistent cough a common side effect of taking Ratipred?

A persistent, dry cough is generally not a frequently reported side effect for this medicine in clinical trials, unlike some other blood pressure medications. If a cough develops while taking this drug, the symptom can be discussed with a healthcare provider.

Q: Can Ratipred affect potassium levels, and is this something to monitor?

Yes, regulatory information indicates that Ratipred can affect potassium levels in the blood. The diuretic component may sometimes cause potassium levels to drop (hypokalemia), while the Irbesartan component can potentially cause them to rise (hyperkalemia). Monitoring of serum electrolytes, including potassium, may be recommended as part of the treatment protocol.

Q: Can taking Ratipred make you feel dehydrated, especially in hot weather?

Because the medicine contains a diuretic that increases fluid and salt removal, it can contribute to fluid loss. Official safety information advises that becoming dehydrated, such as from excessive sweating in hot weather, can cause a drop in blood pressure. This may potentially lead to lightheadedness or feeling faint.

Q: Does Ratipred have any effect on blood sugar levels in diabetic patients?

Official product information notes that the Hydrochlorothiazide component may impair glucose tolerance. This potential effect may necessitate a dosage review of antidiabetic medications by a healthcare provider.

Q: What research is available on the long-term safety profile of Ratipred?

The safety profile is derived from controlled clinical trials, primarily focused on short- to medium-term outcomes. Regulatory summaries note that the long-term effects over many years are not fully established, and long-term comparative evidence against a control group is often limited.

Q: Does Ratipred offer any protection against stroke or heart attack?

According to regulatory sources, lowering blood pressure with this medication is associated with a reduced cardiovascular risk. This includes a reduced risk of fatal and nonfatal strokes and myocardial infarctions (heart attacks).

Q: Can Ratipred cause stomach upset, like nausea or diarrhea?

Official regulatory documents list gastrointestinal side effects such as nausea and vomiting as common (may affect up to 1 in 10 people). If these symptoms become severe or persistent, they should be discussed with a healthcare professional.

Q: How does the diuretic component (hydrochlorothiazide) in some Ratipred combinations work alongside irbesartan?

The two ingredients provide a synergistic effect, working together to achieve a combined result in lowering blood pressure. Irbesartan also helps prevent the body's counter-regulatory activation of the Renin-Angiotensin-Aldosterone System (RAAS) that is typically stimulated by the fluid-removing action of the diuretic.

Q: Does Ratipred start working immediately, or does it take time to see the full blood pressure effect?

Regulatory information states that the blood pressure-lowering effect begins after the first dose. However, the full intended therapeutic effect is generally achieved after approximately two weeks of consistent, daily treatment.

Q: How long do the effects of one Ratipred dose typically last?

The drug is formulated and intended to be taken once daily. The official label indicates that the action of the medicine provides sustained 24-hour control of blood pressure, with effects lasting throughout the full dosing interval.

Q: Is it normal to feel dizzy or lightheaded when first starting Ratipred?

Dizziness is listed as a common side effect in the official product information. Regulatory documents note that effects like dizziness may be more noticeable when a person first starts taking the medicine or when their dose is being adjusted.

Q: What should I do if I forget to take my Ratipred at the usual time?

Regulatory information provides specific instructions for managing a missed dose, typically advising patients on when to take the missed dose versus skipping it. These instructions can be found in the patient information leaflet.

Q: Does alcohol consumption interfere with how Ratipred works?

Yes, official labeling warns that consuming alcohol may have an additional effect in lowering blood pressure. This combination can increase the risk of side effects like dizziness, lightheadedness, or fainting.

Q: Can Ratipred be taken with or without food?

According to the official method of administration in the product information, Ratipred tablets can be taken either with or without food.

Q: Is it necessary to take Ratipred at the exact same time every day for it to be effective?

The drug is intended for once-daily use. Official patient counseling recommends taking it at about the same time each day to maintain a consistent level of medicine in the body, which helps ensure stable 24-hour blood pressure control.

Q: What is the risk of taking Ratipred if a person has pre-existing heart problems?

Regulatory documents advise that the medicine should be used with caution in patients with pre-existing conditions, such as severe congestive heart failure. In these cases, there is a risk that the medication could lead to kidney problems.

Q: Why is Ratipred typically taken once a day?

The drug is typically prescribed for once-daily dosing because its pharmacological action provides sustained effects. This means that one dose is effective enough to maintain adequate blood pressure control throughout the full 24-hour period.

Q: Can men experience sexual side effects, like erectile dysfunction, while taking Ratipred?

Official reports of undesirable effects list sexual dysfunction as an uncommon side effect. Any concerns regarding sexual performance or changes should be reported to a healthcare provider for evaluation.

Q: Is Ratipred considered a diuretic, or does it contain one?

Ratipred is classified as a fixed-dose combination product. It contains two active ingredients: irbesartan (an angiotensin receptor blocker) and hydrochlorothiazide, which is the diuretic component.

Q: Is Ratipred available as a generic drug, and is it the same as the brand name?

The active ingredients in Ratipred (irbesartan/hydrochlorothiazide) are available as a generic combination product. Generic medicines are required by the FDA to be bioequivalent to the original brand-name drug, meaning they work in the body in the same way.

Q: Are there specific patient groups where Ratipred may be less effective?

Clinical studies have assessed the medicine's effect across different patient groups, including race. Official information notes that the blood pressure-lowering effect was observed to be somewhat less in black patients, who often have low-renin hypertension.

Q: What kind of monitoring (like blood tests) is usually required while taking Ratipred?

Regulatory documents recommend the monitoring of kidney function and serum electrolytes. Monitoring may involve blood tests to check for changes in these levels, such as potassium.

Q: Can Ratipred affect a person's ability to drive or operate machinery?

Since the medicine can cause dizziness, lightheadedness, or fainting, official labeling advises caution. Patients are advised to use caution and determine how the drug affects them before engaging in activities that require alertness, such as driving or operating hazardous machinery.

Q: Why is Ratipred not recommended for people with a very low salt diet?

The medicine is not recommended for use in patients who are volume-depleted, meaning they have low fluid levels. A very low-salt or low-sodium diet can sometimes contribute to this condition, which can cause an overly large drop in blood pressure when the medication is taken.

Q: What is the average time for Ratipred to reach a stable level in the bloodstream (steady-state)?

Official pharmacokinetic data indicates that the active ingredient, Irbesartan, reaches stable levels in the bloodstream (known as steady-state concentrations) relatively quickly. This stable level is typically achieved within approximately three days of repeated once-daily dosing.

Q: Is it normal for my urine color or frequency to change after starting Ratipred?

Yes, because the medicine contains a diuretic, it will increase the amount and frequency of urination. According to the official safety profile, abnormal urination is listed as a common side effect.

Q: Can taking Ratipred lead to a temporary increase in thirst?

While thirst itself is not listed as a common side effect, the diuretic component can cause fluid loss. The patient information warns against becoming dehydrated, which may lead to symptoms like increased thirst.

Q: Do older adults require special consideration or monitoring when taking Ratipred?

Official geriatric use studies have not identified specific age-related issues that would limit the usefulness of Ratipred in older adults. Generally, the official documents state that no special dosage adjustment is required in elderly patients based on age alone.

Q: Is Ratipred safe for children to take for high blood pressure?

Official regulatory documents state that Ratipred is not recommended for use in children and adolescents. This is because safety and efficacy for use in pediatric patients have not been established.

How should Ratipred be stored and disposed of?

How to Store and Dispose of Ratipred?

The storage and disposal of Ratipred tablets are strictly governed by regulatory requirements to maintain product integrity and ensure public safety.

Storage Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, between 20^circC and 25^circC (68^circF and 77^circF), with brief excursions permitted up to 30^circC (86^circF).
Protection Keep the medicine in its original, tightly closed container, protected from excessive heat, moisture, and freezing.
Child Safety Keep out of the sight and reach of children.

Official Disposal Instructions

Expired or unused Ratipred must be discarded using officially sanctioned methods to protect the environment. Regulatory guidance states that the medicine must not be flushed down a toilet or poured into a drain. Instead, utilize a designated medicine take-back program or follow local guidelines for proper household trash disposal of unused pharmaceuticals.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ratipred found in:

A-Z Index: